Bioleaders Corporation (KQ:142760) — Market Cap & Net Worth
Market Cap & Net Worth: Bioleaders Corporation (142760)
Bioleaders Corporation (KQ:142760) has a market capitalization of $13.20 Million (₩19.48 Billion) as of August 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #26305 globally and #1975 in its home market, demonstrating a 16.37% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioleaders Corporation's stock price ₩462.00 by its total outstanding shares 42166980 (42.17 Million). See reinvestment intensity of Bioleaders Corporation to understand how much of operating cash flow is reinvested back into capital assets.
Bioleaders Corporation Market Cap History: 2016 to 2026
Bioleaders Corporation's market capitalization history from 2016 to 2026. Data shows change from $158.21 Million to $13.20 Million (-28.04% CAGR).
Index Memberships
Bioleaders Corporation is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$206.59 Billion | 0.01% | #1073 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$206.59 Billion | 0.01% | #1073 of 1384 |
Weight: Bioleaders Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bioleaders Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioleaders Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Bioleaders Corporation's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $158.21 Million | $2.50 Billion | -$5.90 Billion | 0.06x | N/A |
| 2017 | $254.88 Million | $7.61 Billion | -$6.65 Billion | 0.03x | N/A |
| 2018 | $316.67 Million | $86.07 Billion | -$17.23 Billion | 0.00x | N/A |
| 2019 | $180.26 Million | $72.88 Billion | -$28.05 Billion | 0.00x | N/A |
| 2020 | $180.31 Million | $80.45 Billion | -$21.14 Billion | 0.00x | N/A |
| 2021 | $238.61 Million | $101.17 Billion | -$19.77 Billion | 0.00x | N/A |
| 2022 | $102.02 Million | $100.41 Billion | -$23.14 Billion | 0.00x | N/A |
| 2023 | $60.87 Million | $18.25 Billion | $8.01 Billion | 0.00x | 0.01x |
| 2024 | $34.55 Million | $15.63 Billion | -$6.99 Billion | 0.00x | N/A |
| 2025 | $50.72 Million | $11.22 Billion | -$13.05 Billion | 0.00x | N/A |
Competitor Companies of 142760 by Market Capitalization
Companies near Bioleaders Corporation in the global market cap rankings as of August 5, 2026.
Key companies related to Bioleaders Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Bioleaders Corporation Historical Marketcap From 2016 to 2026
Between 2016 and today, Bioleaders Corporation's market cap moved from $158.21 Million to $ 13.20 Million, with a yearly change of -28.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩13.20 Million | -73.97% |
| 2025 | ₩50.72 Million | +46.82% |
| 2024 | ₩34.55 Million | -43.24% |
| 2023 | ₩60.87 Million | -40.34% |
| 2022 | ₩102.02 Million | -57.25% |
| 2021 | ₩238.61 Million | +32.33% |
| 2020 | ₩180.31 Million | +0.03% |
| 2019 | ₩180.26 Million | -43.08% |
| 2018 | ₩316.67 Million | +24.25% |
| 2017 | ₩254.88 Million | +61.10% |
| 2016 | ₩158.21 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Bioleaders Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.20 Million USD |
| MoneyControl | $13.20 Million USD |
| MarketWatch | $13.20 Million USD |
| marketcap.company | $13.20 Million USD |
| Reuters | $13.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bioleaders Corporation
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and… Read more